Amphastar Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amphastar Pharma (AMPH).

Price Target Range — 12 Quarters

Analyst Consensus — 5 Analysts

4Hold

1Sell

Consensus RatingOverweight# Analysts5Avg. Consensus PT$28Upside to Avg. PT+8.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 18, 2026	Barclays	Glen Santangelo	PT Raise	Equal-Weight	$20→$23
Aug 7, 2026	Piper Sandler	David Amsellem	PT Cut	Neutral	$21→$20
Aug 7, 2026	Wells Fargo	Benjamin Burnett	PT Raise	Equal-Weight	$19→$20
Jun 29, 2026	B of A Securities	Jason Gerberry	Downgrade	Neutral→Underperform	$25→$20
Jun 3, 2026	Barclays	Glen Santangelo	PT Cut	Equal-Weight	$23→$20
May 14, 2026	Wells Fargo	Benjamin Burnett	Downgrade	Overweight→Equal-Weight	$30→$19
May 11, 2026	Piper Sandler	David Amsellem	PT Cut	Neutral	$25→$21
May 8, 2026	Needham	Serge Belanger	Downgrade	Buy→Hold	—
Apr 21, 2026	Jefferies	Dennis Ding	Downgrade	Buy→Hold	$30→$22
Apr 8, 2026	Barclays	Glen Santangelo	PT Cut	Equal-Weight	$30→$23
Feb 27, 2026	Wells Fargo	Benjamin Burnett	PT Cut	Overweight	$34→$30
Feb 27, 2026	Needham	Serge Belanger	PT Cut	Buy	$34→$30
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Equal-Weight	$30
Nov 7, 2025	Needham	Serge Belanger	PT Cut	Buy	$36→$34
Oct 22, 2025	Needham	Serge Belanger	Maintained	Buy	$36
Aug 26, 2025	B of A Securities	Jason Gerberry	PT Raise	Neutral	$28→$32
Aug 12, 2025	Needham	Serge Belanger	Upgrade	Hold→Buy	$36
Aug 8, 2025	Piper Sandler	David Amsellem	PT Cut	Neutral	$30→$25
May 12, 2025	JP Morgan	Ekaterina Knyazkova	Downgrade	Overweight→Neutral	$45→$30
May 8, 2025	Wells Fargo	Cerena Chen	PT Cut	Overweight	$40→$35

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

Piper Sandler analyst David Amsellem maintains Amphastar Pharma (NASDAQ:AMPH) with a Neutral and lowers the price target from $21 to $20.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

Wells Fargo analyst Benjamin Burnett maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and raises the price target from $19 to $20.

Benzinga Newsdesk

This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed outlook on top stocks. See all changes including upgrades, downgrades, and initiations on analyst ratings page.

Avi Kapoor

PRO
B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

B of A Securities analyst Jason Gerberry downgrades Amphastar Pharma (NASDAQ:AMPH) from Neutral to Underperform and lowers the price target from $25 to $20.

Benzinga Newsdesk

PRO
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

Barclays analyst Glen Santangelo maintains Amphastar Pharma (NASDAQ:AMPH) with a Equal-Weight and lowers the price target from $23 to $20.

Benzinga Newsdesk

PRO
Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

Wells Fargo analyst Benjamin Burnett downgrades Amphastar Pharma (NASDAQ:AMPH) from Overweight to Equal-Weight and lowers the price target from $30 to $19.

Benzinga Newsdesk

Amphastar Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Amphastar Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

PRO
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

PRO
B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

PRO
Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

People Also Watch

People Also Watch

Amphastar Pharmaceuticals Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Amphastar Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

PROWells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

PROB of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

PROBarclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

PROWells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19

People Also Watch

People Also Watch

PRO
Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20

PRO
Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20

PRO
B of A Securities Downgrades Amphastar Pharma to Underperform, Lowers Price Target to $20

PRO
Barclays Maintains Equal-Weight on Amphastar Pharma, Lowers Price Target to $20

PRO
Wells Fargo Downgrades Amphastar Pharma to Equal-Weight, Lowers Price Target to $19